Krystal Biotech Inc

NASDAQ:KRYS  
68.43
+0.48 (+0.71%)
Products

Krystal Biotech Submits BLA To FDA Seeking Approval Of Dystrophic Epidermolysis Bullosa Treatment

Published: 06/22/2022 11:31 GMT
Krystal Biotech Inc (KRYS) - Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-vec for the Treatment of Patients With Dystrophic Epidermolysis Bullosa.
Krystal Biotech Inc - Anticipates Submission of a Marketing Authorization Application With European Medical Agency (ema) in 2h 2022.